Head and neck for Viralytics

By Kate McDonald
Tuesday, 09 December, 2008

Sydney biotech Viralytics has been authorised to start a trial of its Cavatak oncolytic virus technology in head and neck cancers.

The company is running Phase I trials of the technology in late stage melanoma, prostate and breast cancers.

The new trial will involve nine patients with recurrent, inoperable tumours of the head and neck.

Cavatak is a coxsackievirus-based formulation which attaches itself to receptors on the cell surface that are highly expressed in some solid tumours.

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd